title: Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
abstract: Susceptibility (18 antimicrobial agents including high-dose tobramycin) and checkerboard synergy (23 combinations) studies were performed for 2,621 strains of Burkholderia cepacia complex isolated from 1,257 cystic fibrosis patients. Minocycline, meropenem, and ceftazidime were the most active, inhibiting 38%, 26%, and 23% of strains, respectively. Synergy was rarely noted (range, 1% to 15% of strains per antibiotic combination).
authors.affiliation: Division of Infectious Diseases, Department of Pediatrics, Columbia University, College of Physicians & Surgeons, 650 West 168th Street, PH 4 West Room 470, New York, NY 10032, USA.
authors.forename: Juyan
authors.initials: J
authors.lastname: Zhou
authors.forename: Yunhua
authors.initials: Y
authors.lastname: Chen
authors.forename: Setareh
authors.initials: S
authors.lastname: Tabibi
authors.forename: Luis
authors.initials: L
authors.lastname: Alba
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Garber
authors.forename: Lisa
authors.initials: L
authors.lastname: Saiman
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D019121:Burkholderia Infections / Q000382:microbiology*; D042602:Burkholderia cepacia complex / Q000187:drug effects*; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial; D004357:Drug Synergism; D006801:Humans; D008826:Microbial Sensitivity Tests
chemical_list: D000900:Anti-Bacterial Agents